Nanomedicine for brain cancer
CNS tumors remain among the deadliest forms of cancer, resisting conventional and new
treatment approaches, with mortality rates staying practically unchanged over the past 30 …
treatment approaches, with mortality rates staying practically unchanged over the past 30 …
Signaling pathways in brain tumors and therapeutic interventions
S Li, C Wang, J Chen, Y Lan, W Zhang… - … and Targeted Therapy, 2023 - nature.com
Brain tumors, although rare, contribute to distinct mortality and morbidity at all ages.
Although there are few therapeutic options for brain tumors, enhanced biological …
Although there are few therapeutic options for brain tumors, enhanced biological …
Cancer cell-mitochondria hybrid membrane coated Gboxin loaded nanomedicines for glioblastoma treatment
Y Zou, Y Sun, Y Wang, D Zhang, H Yang… - Nature …, 2023 - nature.com
Glioblastoma (GBM) remains the most lethal malignant tumours. Gboxin, an oxidative
phosphorylation inhibitor, specifically restrains GBM growth by inhibiting the activity of F0F1 …
phosphorylation inhibitor, specifically restrains GBM growth by inhibiting the activity of F0F1 …
Brain co‐delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy
Glioblastoma (GBM) is an intractable malignancy with high recurrence and mortality.
Combinatorial therapy based on temozolomide (TMZ) and cisplatin (CDDP) shows …
Combinatorial therapy based on temozolomide (TMZ) and cisplatin (CDDP) shows …
Brain co‐delivery of first‐line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy
Glioblastoma (GBM) is a central nervous system tumor with poor prognosis due to the rapid
development of resistance to mono chemotherapy and poor brain targeted delivery …
development of resistance to mono chemotherapy and poor brain targeted delivery …
A virus‐mimicking nucleic acid nanogel reprograms microglia and macrophages for glioblastoma therapy
X Gao, S Li, F Ding, X Liu, Y Wu, J Li, J Feng… - Advanced …, 2021 - Wiley Online Library
Immunotherapy is recognized as one of the most promising approaches to treat cancers.
However, its effect in glioblastoma (GBM) treatment is insufficient, which can in part be …
However, its effect in glioblastoma (GBM) treatment is insufficient, which can in part be …
Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma
D Martínez Bedoya, V Dutoit, D Migliorini - Frontiers in immunology, 2021 - frontiersin.org
Chimeric antigen receptor (CAR) T cell therapy has emerged as one of the major
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
D Kreatsoulas, C Bolyard, BX Wu, H Cam… - Journal of Hematology & …, 2022 - Springer
Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …
Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional …
Background Veledimex (VDX)-regulatable interleukin-12 (IL-12) gene therapy in recurrent
glioblastoma (rGBM) was reported to show tumor infiltration of CD8+ T cells, encouraging …
glioblastoma (rGBM) was reported to show tumor infiltration of CD8+ T cells, encouraging …
Meta-analysis of the make-up and properties of in vitro models of the healthy and diseased blood–brain barrier
In vitro models of the human blood–brain barrier (BBB) are increasingly used to develop
therapeutics that can cross the BBB for treating diseases of the central nervous system. Here …
therapeutics that can cross the BBB for treating diseases of the central nervous system. Here …